BriaCell Therapeutics Corp. (BCTXW)
USD 0.1
(-1.67%)
USD 0.1
(-1.67%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 33.33 Million USD | 43.22% |
| 2023 | 23.27 Million USD | 687002.72% |
| 2022 | -3388.00 USD | 99.91% |
| 2021 | -3.68 Million USD | -166.5% |
| 2020 | -1.38 Million CAD | -46.29% |
| 2019 | -946.42 Thousand CAD | 11.14% |
| 2018 | -1.06 Million CAD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 1.66 Million CAD | 15.71% |
| 2015 | 1.44 Million CAD | 229.42% |
| 2014 | 437.27 Thousand CAD | 3.07% |
| 2013 | 424.25 Thousand CAD | -23.12% |
| 2012 | 551.84 Thousand CAD | -47.6% |
| 2011 | 1.05 Million CAD | 224.5% |
| 2010 | 324.56 Thousand CAD | 38.78% |
| 2009 | 233.87 Thousand CAD | 104.93% |
| 2008 | 114.12 Thousand CAD | -11.57% |
| 2007 | 129.05 Thousand CAD | 1404.03% |
| 2006 | 8580.77 CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 9.22 Million USD | -6.1% |
| 2024 Q4 | 5.76 Million USD | -37.51% |
| 2024 Q1 | 8.5 Million USD | 10.35% |
| 2024 Q2 | 9.82 Million USD | 15.6% |
| 2023 Q4 | 7.7 Million USD | 35.74% |
| 2023 FY | 23.27 Million USD | 687002.72% |
| 2023 Q3 | 5.67 Million USD | 26.54% |
| 2023 Q2 | 4.48 Million USD | -20.97% |
| 2023 Q1 | 5.67 Million USD | 26.54% |
| 2022 Q2 | -2.19 Million USD | -146.77% |
| 2022 Q3 | -2.3 Million USD | -4.71% |
| 2022 Q1 | -891.03 Thousand USD | 14.24% |
| 2022 FY | -3388.00 USD | 99.91% |
| 2022 Q4 | 4.48 Million USD | 294.86% |
| 2021 Q3 | -2.39 Million CAD | -1229.99% |
| 2021 FY | -3.68 Million USD | -166.5% |
| 2021 Q4 | -1.03 Million USD | 56.61% |
| 2021 Q2 | -180.05 Thousand CAD | 23.02% |
| 2021 Q1 | -233.91 Thousand CAD | -12.96% |
| 2020 Q3 | -298.2 Thousand CAD | 40.53% |
| 2020 Q1 | -416.53 Thousand CAD | -31.49% |
| 2020 FY | -1.38 Million CAD | -46.29% |
| 2020 Q4 | -207.07 Thousand CAD | 30.56% |
| 2020 Q2 | -501.41 Thousand CAD | -20.38% |
| 2019 Q1 | 980.12 Thousand CAD | -32.0% |
| 2019 FY | -946.42 Thousand CAD | 11.14% |
| 2019 Q4 | -316.77 Thousand CAD | -11.69% |
| 2019 Q3 | -283.6 Thousand CAD | -120.83% |
| 2019 Q2 | 1.36 Million CAD | 38.89% |
| 2018 Q2 | 802.04 Thousand CAD | 59.44% |
| 2018 Q1 | 503.02 Thousand CAD | -53.24% |
| 2018 FY | -1.06 Million CAD | 0.0% |
| 2018 Q4 | 1.44 Million CAD | 29.92% |
| 2018 Q3 | 1.1 Million CAD | 38.32% |
| 2017 Q2 | 338.08 Thousand CAD | 4.02% |
| 2017 FY | - USD | -100.0% |
| 2017 Q1 | 325.02 Thousand CAD | 58.06% |
| 2017 Q4 | 1.07 Million CAD | 24.79% |
| 2017 Q3 | 862.09 Thousand CAD | 155.0% |
| 2016 FY | 1.66 Million CAD | 15.71% |
| 2016 Q3 | 272.51 Thousand CAD | -64.85% |
| 2016 Q4 | 205.62 Thousand CAD | -24.54% |
| 2016 Q2 | 775.31 Thousand CAD | 148.13% |
| 2016 Q1 | 312.45 Thousand CAD | 4.48% |
| 2015 Q2 | 664.89 Thousand CAD | 457.88% |
| 2015 FY | 1.44 Million CAD | 229.42% |
| 2015 Q4 | 299.06 Thousand CAD | -22.56% |
| 2015 Q1 | 119.18 Thousand CAD | -32.03% |
| 2015 Q3 | 386.21 Thousand CAD | -41.91% |
| 2014 Q2 | 83.1 Thousand CAD | 2.79% |
| 2014 Q1 | 80.84 Thousand CAD | -12.43% |
| 2014 Q3 | 99.92 Thousand CAD | 20.24% |
| 2014 Q4 | 175.35 Thousand CAD | 75.49% |
| 2014 FY | 437.27 Thousand CAD | 3.07% |
| 2013 Q1 | 106.42 Thousand CAD | -17.82% |
| 2013 FY | 424.25 Thousand CAD | -23.12% |
| 2013 Q4 | 92.32 Thousand CAD | -22.37% |
| 2013 Q2 | 108.88 Thousand CAD | 2.31% |
| 2013 Q3 | 118.92 Thousand CAD | 9.22% |
| 2012 Q2 | 141.74 Thousand CAD | -5.41% |
| 2012 FY | 551.84 Thousand CAD | -47.6% |
| 2012 Q1 | 149.84 Thousand CAD | -70.36% |
| 2012 Q4 | 129.49 Thousand CAD | 3.0% |
| 2012 Q3 | 125.72 Thousand CAD | -11.3% |
| 2011 FY | 1.05 Million CAD | 224.5% |
| 2011 Q2 | 184.95 Thousand CAD | 71.55% |
| 2011 Q1 | 107.81 Thousand CAD | 491.48% |
| 2011 Q3 | 235.27 Thousand CAD | 27.21% |
| 2011 Q4 | 505.6 Thousand CAD | 114.9% |
| 2010 Q2 | 92.97 Thousand CAD | 63.05% |
| 2010 Q1 | 57.02 Thousand CAD | -59.41% |
| 2010 Q3 | 189.63 Thousand CAD | 103.96% |
| 2010 Q4 | -27.54 Thousand CAD | -114.52% |
| 2010 FY | 324.56 Thousand CAD | 38.78% |
| 2009 Q4 | 140.48 Thousand CAD | 1473.14% |
| 2009 Q3 | 8929.93 CAD | -73.8% |
| 2009 FY | 233.87 Thousand CAD | 104.93% |
| 2009 Q2 | 34.08 Thousand CAD | -34.65% |
| 2009 Q1 | 52.16 Thousand CAD | -7.93% |
| 2008 Q3 | 28.32 Thousand CAD | 45.0% |
| 2008 Q1 | 10.3 Thousand CAD | -73.83% |
| 2008 Q2 | 19.53 Thousand CAD | 89.61% |
| 2008 FY | 114.12 Thousand CAD | -11.57% |
| 2008 Q4 | 56.66 Thousand CAD | 100.06% |
| 2007 Q4 | 39.36 Thousand CAD | 202.9% |
| 2007 Q2 | 44.91 Thousand CAD | 57.64% |
| 2007 Q3 | 12.99 Thousand CAD | -71.07% |
| 2007 FY | 129.05 Thousand CAD | 1404.03% |
| 2007 Q1 | 28.49 Thousand CAD | 0.0% |
| 2006 FY | 8580.77 CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 87.89% |
| Alkermes plc | 996.24 Million USD | 96.654% |
| Agenus Inc. | 78.18 Million USD | 57.369% |
| Aptorum Group Limited | 10.56 Thousand USD | -315346.489% |
| Ardelyx, Inc. | 169.93 Million USD | 80.387% |
| Dyadic International, Inc. | 9.15 Million USD | -264.156% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -49.778% |
| Lantern Pharma Inc. | 17.87 Million USD | -86.435% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -395.103% |
| Novavax, Inc. | 779.12 Million USD | 95.722% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 58.883% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 59.45% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -71.641% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -12.579% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | 37.263% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 91.24% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -37.124% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | 11.986% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -8.317% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 60.657% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -90.927% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 80.212% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -1.88% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 79.141% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 98.148% |
| AlloVir, Inc. | 180.93 Million USD | 81.579% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 92.522% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -12.291% |
| Bicycle Therapeutics plc | 216.92 Million USD | 84.635% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 80.611% |
| ChromaDex Corporation | 56.37 Million USD | 40.882% |
| Chimerix, Inc. | 93.38 Million USD | 64.31% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -139.619% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 77.859% |
| CRISPR Therapeutics AG | 463.49 Million USD | 92.809% |
| Precision BioSciences, Inc. | 92.46 Million USD | 63.953% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 86.88% |
| Fortress Biotech, Inc. | 200.19 Million USD | 83.351% |
| Fortress Biotech, Inc. | 200.19 Million USD | 83.351% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -1.784% |
| ImmuCell Corporation | 9.61 Million USD | -246.562% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 78.88% |
| Immix Biopharma, Inc. | 16.14 Million USD | -106.492% |
| Incyte Corporation | 1.19 Billion USD | 97.2% |
| Innoviva, Inc. | 132.15 Million USD | 74.779% |
| IO Biotech, Inc. | 91.44 Million USD | 63.551% |
| Jaguar Health, Inc. | 42.01 Million USD | 20.671% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 80.31% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 60.473% |
| ContextLogic Inc. | 387 Million USD | 91.388% |
| MiMedx Group, Inc. | 229.72 Million USD | 85.491% |
| MEI Pharma, Inc. | 34.78 Million USD | 4.183% |
| NextCure, Inc. | 67.63 Million USD | 50.722% |
| Onconetix, Inc. | 34.9 Million USD | 4.519% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -161.494% |
| Opthea Limited | 191.96 Million USD | 82.638% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -1111.305% |
| Vaxcyte, Inc. | 468.04 Million USD | 92.879% |
| PDS Biotechnology Corporation | 43.04 Million USD | 22.57% |
| Precigen, Inc. | 84.18 Million USD | 60.407% |
| Pharming Group N.V. | 225.49 Million USD | 85.219% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 80.14% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | 54.069% |
| PureTech Health plc | 144.59 Million USD | 76.95% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 74.413% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 86.405% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -37.124% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 85.425% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -8.008% |
| Acelyrin, Inc. | 422.06 Million USD | 92.103% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -258392.911% |
| Summit Therapeutics Inc. | 87.68 Million USD | 61.989% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | 10.074% |
| Senti Biosciences, Inc. | 94.7 Million USD | 64.806% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 73.024% |
| Elevation Oncology, Inc. | 45.44 Million USD | 26.658% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -13.102% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -745.502% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 74.783% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | 2.215% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -294.392% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 81.616% |
| Seer, Inc. | 110.49 Million USD | 69.834% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | 52.786% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 64.344% |
| ESSA Pharma Inc. | 32.13 Million USD | -3.722% |
| GlycoMimetics, Inc. | 39.28 Million USD | 15.159% |
| GT Biopharma, Inc. | 13.57 Million USD | -145.507% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 84.838% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 83.427% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 87.152% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | 41.278% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | 38.369% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -235.392% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 91.741% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -76.079% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 34.251% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 87.164% |
| Aptose Biosciences Inc. | 52.35 Million USD | 36.34% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -131.292% |
| Soligenix, Inc. | 7.79 Million USD | -327.569% |
| Century Therapeutics, Inc. | 56.07 Million USD | 40.557% |
| Kura Oncology, Inc. | 165.8 Million USD | 79.898% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 70.893% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -300.65% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -1243.067% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 69.052% |
| Autolus Therapeutics plc | 196.72 Million USD | 83.058% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 60.629% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 71.379% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -71.955% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 89.641% |
| GRI Bio, Inc. | 11.33 Million USD | -194.175% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -372.385% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 74.595% |
| IGM Biosciences, Inc. | 265.59 Million USD | 87.451% |
| INmune Bio, Inc. | 29.89 Million USD | -11.487% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 80.684% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 17.324% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -108.582% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -111.733% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | 46.327% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 69.002% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 87.91% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 88.943% |
| Verastem, Inc. | 92.08 Million USD | 63.805% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -85.797% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 82.054% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 72.547% |
| Histogen Inc. | 14.27 Million USD | -133.535% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -107.688% |
| Surrozen, Inc. | 18.55 Million USD | -79.677% |
| Organovo Holdings, Inc. | 14.91 Million USD | -123.467% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -554.784% |
| Ovid Therapeutics Inc. | 59.67 Million USD | 44.146% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -29.957% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | 29.094% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -336.667% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 81.29% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | 31.204% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 86.396% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -116.9% |
| Apollomics, Inc. | 54.14 Million USD | 38.437% |
| Amarin Corporation plc | 272.35 Million USD | 87.762% |
| Mesoblast Limited | 5.9 Million USD | -464.725% |
| Turnstone Biologics Corp. | 78.33 Million USD | 57.454% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 86.347% |
| Synaptogenix, Inc. | 8.31 Million USD | -300.898% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -128.507% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 86.829% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -277.411% |
| Exelixis, Inc. | 1.58 Billion USD | 97.9% |
| Better Therapeutics, Inc. | 38.26 Million USD | 12.89% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 85.637% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 96.103% |
| NLS Pharmaceutics AG | 11.8 Million USD | -182.289% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -314.455% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -11.126% |
| Gritstone bio, Inc. | 148.37 Million USD | 77.536% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 51.598% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -103.726% |
| Avid Bioservices, Inc. | 25.99 Million USD | -28.212% |
| Insmed Incorporated | 949.26 Million USD | 96.489% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -112.432% |
| MediWound Ltd. | 18.86 Million USD | -76.649% |
| OmniAb, Inc. | 83.89 Million USD | 60.272% |
| Alector, Inc. | 248.8 Million USD | 86.604% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 85.775% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | 36.212% |
| Zai Lab Limited | 547.47 Million USD | 93.912% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 91.639% |
| Aura Biosciences, Inc. | 84.99 Million USD | 60.784% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 86.514% |
| Immunic, Inc. | 99.22 Million USD | 66.409% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 79.039% |
| Veracyte, Inc. | 357.93 Million USD | 90.688% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.63% |
| FibroGen, Inc. | 398.11 Million USD | 91.628% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -134.554% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -383.89% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -367.742% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 98.976% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -28.822% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 89.471% |
| TG Therapeutics, Inc. | 198.47 Million USD | 83.207% |
| Galecto, Inc. | 35.62 Million USD | 6.447% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 18.086% |
| Fortrea Holdings Inc. | 457.3 Million USD | 92.712% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | 38.594% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -15.417% |
| XBiotech Inc. | 37.51 Million USD | 11.143% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 51.598% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -61.413% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 76.538% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 66.359% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 69.896% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 96.522% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -15.549% |
| Vaxxinity, Inc. | 56.05 Million USD | 40.536% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 92.26% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -49.407% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 69.937% |
| NexImmune, Inc. | 28.16 Million USD | -18.328% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -502.611% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -86.279% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 98.816% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -30.917% |
| Scopus BioPharma Inc. | 11.71 Million USD | -184.511% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 73.769% |
| Ainos, Inc. | 12.95 Million USD | -157.322% |
| Pluri Inc. | 22.48 Million USD | -48.265% |
| Prothena Corporation plc | 282.4 Million USD | 88.198% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 83.337% |
| Celularity Inc. | 215.05 Million USD | 84.502% |
| Rallybio Corporation | 78.93 Million USD | 57.774% |
| Cue Biopharma, Inc. | 19.54 Million USD | -70.556% |
| MeiraGTx Holdings plc | 151.07 Million USD | 77.938% |
| Omeros Corporation | 94.75 Million USD | 64.824% |
| Humacyte, Inc. | 23.49 Million USD | -41.848% |
| Immunocore Holdings plc | 308.04 Million USD | 89.18% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -883.188% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 61.63% |
| Blueprint Medicines Corporation | 722.86 Million USD | 95.389% |
| CalciMedica, Inc. | 21.81 Million USD | -52.771% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 55.358% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 79.239% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 80.542% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 88.699% |
| Pulmatrix, Inc. | 22.03 Million USD | -51.239% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | 3.601% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 62.494% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 93.957% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | 54.06% |
| Cytokinetics, Incorporated | 173.61 Million USD | 80.802% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 3.164% |
| Nutriband Inc. | 5.73 Million USD | -481.268% |
| Protara Therapeutics, Inc. | 43.61 Million USD | 23.578% |
| Vor Biopharma Inc. | 126.03 Million USD | 73.555% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 97.197% |
| Evogene Ltd. | 27.79 Million USD | -19.936% |
| ProKidney Corp. | 151.52 Million USD | 78.003% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 55.066% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -333.295% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 94.574% |
| CorMedix Inc. | 48.95 Million USD | 31.921% |
| BioLineRx Ltd. | 50.8 Million USD | 34.392% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 77.883% |
| Galectin Therapeutics Inc. | 38.07 Million USD | 12.455% |
| Atai Life Sciences N.V. | 125.78 Million USD | 73.502% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 59.174% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 59.058% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 86.803% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -1.802% |
| MediciNova, Inc. | 10.9 Million USD | -205.773% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 74.127% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -359.122% |
| GeoVax Labs, Inc. | 6.02 Million USD | -453.456% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 93.003% |
| Biomea Fusion, Inc. | 126.13 Million USD | 73.576% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 97.459% |
| Mereo BioPharma Group plc | 35.84 Million USD | 7.008% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 82.558% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 85.506% |
| Absci Corporation | 73.66 Million USD | 54.755% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -20.84% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 75.05% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 86.236% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 87.281% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 83.975% |
| Allakos Inc. | 196.05 Million USD | 83.0% |
| Imunon, Inc. | 20.31 Million USD | -64.103% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 70.626% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 90.958% |
| BioAtla, Inc. | 129.68 Million USD | 74.3% |
| NLS Pharmaceutics AG | 11.8 Million USD | -182.289% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -110.377% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 60.75% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | 20.183% |
| XOMA Corporation | 46.46 Million USD | 28.265% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 70.019% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 76.604% |
| aTyr Pharma, Inc. | 12.97 Million USD | -156.8% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 67.845% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 80.72% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 86.917% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | 10.901% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -305.238% |
| Akari Therapeutics, Plc | 16.8 Million USD | -98.322% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -1365.722% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 88.865% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -395.34% |
| UroGen Pharma Ltd. | 138.88 Million USD | 76.002% |
| Sutro Biopharma, Inc. | 243 Million USD | 86.284% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -358.169% |
| Orgenesis Inc. | 45.75 Million USD | 27.159% |
| Entera Bio Ltd. | 8.86 Million USD | -276.186% |
| GH Research PLC | 41.22 Million USD | 19.145% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -29.649% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 59.869% |
| Xencor, Inc. | 306.97 Million USD | 89.142% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -575.572% |
| Replimune Group, Inc. | 234.77 Million USD | 85.803% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -62.666% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 82.622% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -395.34% |
| Portage Biotech Inc. | 18.19 Million USD | -83.142% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -359.122% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 68.245% |
| OncoCyte Corporation | 25.63 Million USD | -30.008% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -446.788% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -190.913% |
| Purple Biotech Ltd. | -22.46 Million USD | 248.351% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -102.246% |
| scPharmaceuticals Inc. | 65.17 Million USD | 48.863% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -294.311% |
| HilleVax, Inc. | 133.34 Million USD | 75.005% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -224.065% |
| Tharimmune, Inc. | 9.45 Million USD | -252.505% |
| Genprex, Inc. | 31.06 Million USD | -7.307% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 82.226% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -6.225% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -4256.873% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -511.907% |
| OKYO Pharma Limited | 8243.57 USD | -404216.043% |
| Savara Inc. | 15.74 Million USD | -111.687% |
| Curis, Inc. | 58.35 Million USD | 42.884% |
| Daré Bioscience, Inc. | 33.6 Million USD | 0.831% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -554.495% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -346.724% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -23.344% |
| BeiGene, Ltd. | 3.28 Billion USD | 98.986% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -67.158% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 93.317% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 78.308% |
| Erasca, Inc. | 141.52 Million USD | 76.449% |
| bluebird bio, Inc. | 240.23 Million USD | 86.126% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -636.255% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 98.091% |
| DBV Technologies S.A. | 92.16 Million USD | 63.835% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -636.255% |
| Moderna, Inc. | 6.39 Billion USD | 99.479% |
| Vincerx Pharma, Inc. | 42.6 Million USD | 21.777% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -132.007% |
| Molecular Templates, Inc. | 63.09 Million USD | 47.171% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | 50.031% |
| Travere Therapeutics, Inc. | 472 Million USD | 92.939% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 76.743% |
| Spruce Biosciences, Inc. | 62.08 Million USD | 46.313% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | 23.227% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 83.986% |
| MacroGenics, Inc. | 217.21 Million USD | 84.656% |
| RenovoRx, Inc. | 11.39 Million USD | -192.472% |
| Adicet Bio, Inc. | 152.03 Million USD | 78.078% |
| Prime Medicine, Inc. | 186.63 Million USD | 82.142% |
| Aditxt, Inc. | 25.95 Million USD | -28.436% |
| Adagene Inc. | 41.83 Million USD | 20.323% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -355.946% |
| Quantum-Si incorporated | 111.65 Million USD | 70.15% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 80.605% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -128.636% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | 6.956% |
| SciSparc Ltd. | 9.01 Million USD | -269.882% |
| Vericel Corporation | 142.04 Million USD | 76.535% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -285.022% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -44.357% |
| Generation Bio Co. | 144.46 Million USD | 76.929% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 59.858% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 61.45% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 88.729% |
| Invivyd, Inc. | 205.75 Million USD | 83.801% |
| Relay Therapeutics, Inc. | 72.15 Million USD | 53.81% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -255.388% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 55.71% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -224.002% |
| 2seventy bio, Inc. | 289.88 Million USD | 88.502% |
| ADMA Biologics, Inc. | 66.58 Million USD | 49.944% |
| Clene Inc. | 41.07 Million USD | 18.852% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -160.231% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | 39.174% |
| GeoVax Labs, Inc. | 6.02 Million USD | -453.456% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 90.533% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | 9.262% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | 1.18% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 67.86% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -2.274% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 80.426% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 95.659% |
| Evaxion Biotech A/S | 22.27 Million USD | -49.664% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 75.41% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 85.81% |
| Trevena, Inc. | 38.41 Million USD | 13.232% |
| Surrozen, Inc. | 18.55 Million USD | -79.677% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 58.309% |
| Cingulate Inc. | 22.75 Million USD | -46.447% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 544.876% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 25.381% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -304.789% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 67.501% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 95.58% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | 46.306% |
| Clearmind Medicine Inc. | 8.74 Million USD | -281.292% |
| Kronos Bio, Inc. | 128.11 Million USD | 73.985% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 60.355% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -1036.388% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 66.943% |
| Statera Biopharma, Inc. | 28.82 Million USD | -15.611% |
| ImmunityBio, Inc. | 362.87 Million USD | 90.815% |
| Korro Bio, Inc. | 84.53 Million USD | 60.572% |
| Kineta, Inc. | 21.15 Million USD | -57.544% |
| BioVie Inc. | 31.95 Million USD | -4.319% |
| Codexis, Inc. | 66.51 Million USD | 49.893% |
| Celularity Inc. | 215.05 Million USD | 84.502% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 85.293% |
| Celcuity Inc. | 66.23 Million USD | 49.676% |
| Virax Biolabs Group Limited | 6.54 Million USD | -409.084% |
| Cibus, Inc. | 320.3 Million USD | 89.594% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | 22.488% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 1.519% |
| IN8bio, Inc. | 30.33 Million USD | -9.866% |
| Kodiak Sciences Inc. | 277.32 Million USD | 87.981% |
| Annexon, Inc. | 143.72 Million USD | 76.81% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 73.877% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -45.489% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -5107.824% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 95.725% |
| Eyenovia, Inc. | 25.4 Million USD | -31.187% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 76.246% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -499.246% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 57.881% |
| Arcellx, Inc. | 200.19 Million USD | 83.352% |
| Cardiff Oncology, Inc. | 45.9 Million USD | 27.385% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 84.599% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -234.74% |
| Moolec Science SA | 52.75 Million USD | 36.816% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | 45.484% |
| Geron Corporation | 70.44 Million USD | 52.684% |
| LAVA Therapeutics N.V. | 46.54 Million USD | 28.384% |
| Royalty Pharma plc | 862.4 Million USD | 96.135% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 64.57% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -257.317% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -47.292% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 83.961% |
| Humacyte, Inc. | 23.49 Million USD | -41.848% |
| Structure Therapeutics Inc. | 102.77 Million USD | 67.57% |
| 89bio, Inc. | 151.2 Million USD | 77.957% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 58.406% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -129.23% |
| Genelux Corporation | 24.33 Million USD | -36.964% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | 1.748% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 80.719% |
| Notable Labs, Ltd. | 14.77 Million USD | -125.661% |
| Liquidia Corporation | 87.98 Million USD | 62.118% |
| Mustang Bio, Inc. | 48.5 Million USD | 31.28% |
| Immunovant, Inc. | 282.7 Million USD | 88.21% |
| Quantum-Si incorporated | 111.65 Million USD | 70.15% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -47.845% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -56.722% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 67.327% |
| Acasti Pharma Inc. | 11.3 Million USD | -194.93% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -45.412% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -108.582% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | 28.387% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -2837.658% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -109.808% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -14.312% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | 19.461% |
| PepGen Inc. | 84.76 Million USD | 60.68% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -12.484% |
| United Therapeutics Corporation | 885.1 Million USD | 96.234% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -45.565% |
| Solid Biosciences Inc. | 104.31 Million USD | 68.049% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -1.847% |
| Immuneering Corporation | 58.41 Million USD | 42.941% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -554.784% |
| Silo Pharma, Inc. | 3.92 Million USD | -749.855% |
| Belite Bio, Inc | 31.66 Million USD | -5.248% |
| XOMA Corporation | 46.46 Million USD | 28.265% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | 50.659% |
| Bionomics Limited | 17.89 Billion USD | 99.814% |
| Apogee Therapeutics, Inc. | 93 Million USD | 64.162% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 193.414% |
| uniQure N.V. | 285.08 Million USD | 88.309% |
| Cassava Sciences, Inc. | 105.95 Million USD | 68.544% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -355.946% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 82.838% |
| Forte Biosciences, Inc. | 32.47 Million USD | -2.627% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -301.144% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -13.387% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -499.246% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -134.554% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -274.959% |
| Altimmune, Inc. | 30.55 Million USD | -9.079% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 92.206% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 193.414% |
| Compugen Ltd. | 43.97 Million USD | 24.2% |
| Peak Bio, Inc. | 1249.13 USD | -2668163.191% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 55.032% |
| Benitec Biopharma Inc. | 22.38 Million USD | -48.915% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 86.295% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -16.771% |
| Zura Bio Limited | 62.63 Million USD | 46.789% |
| PolyPid Ltd. | 21.04 Million USD | -58.375% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -104.781% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -16.771% |
| Instil Bio, Inc. | 85.78 Million USD | 61.147% |
| argenx SE | 1.53 Billion USD | 97.827% |
| Immunome, Inc. | 122.82 Million USD | 72.863% |
| Compass Therapeutics, Inc. | 48.47 Million USD | 31.24% |
| Verona Pharma plc | 67.15 Million USD | 50.366% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -28.762% |
| Shattuck Labs, Inc. | 93.61 Million USD | 64.396% |
| CervoMed Inc. | 14.95 Million USD | -122.828% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | 52.859% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -290.099% |
| Dianthus Therapeutics, Inc. | 51 Million USD | 34.647% |
| Moolec Science SA | 52.75 Million USD | 36.816% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -102.634% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 74.856% |
| AnaptysBio, Inc. | 181.56 Million USD | 81.643% |
| Design Therapeutics, Inc. | 78.19 Million USD | 57.373% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 61.708% |
| NeurAxis, Inc. | 8.82 Million USD | -277.841% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -164.84% |
| Lumos Pharma, Inc. | 38.66 Million USD | 13.798% |
| Achilles Therapeutics plc | 75.25 Million USD | 55.71% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -28.762% |
| 180 Life Sciences Corp. | 13.47 Million USD | -147.302% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -25.762% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -1036.388% |
| Nutriband Inc. | 5.73 Million USD | -481.268% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 69.913% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | 40.111% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | 34.491% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | 49.576% |
| MoonLake Immunotherapeutics | 54.12 Million USD | 38.418% |
| Palisade Bio, Inc. | 13.32 Million USD | -150.226% |
| Tourmaline Bio, Inc. | 45.4 Million USD | 26.6% |
| Beam Therapeutics Inc. | 554.19 Million USD | 93.986% |
| Neurogene Inc. | 55.58 Million USD | 40.035% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 86.587% |
| AEON Biopharma, Inc. | 48.42 Million USD | 31.177% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 65.536% |
| Sesen Bio, Inc. | 78.38 Million USD | 57.477% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 60.098% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -164.8% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 92.61% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 62.078% |
| Athira Pharma, Inc. | 125.46 Million USD | 73.435% |
| Vaccinex, Inc. | 23.45 Million USD | -42.102% |
| HCW Biologics Inc. | 21.02 Million USD | -58.507% |
| XOMA Corporation | 46.46 Million USD | 28.265% |
| Nektar Therapeutics | 190.9 Million USD | 82.541% |
| Arvinas, Inc. | 480 Million USD | 93.056% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -1365.722% |
| Merus N.V. | 200.49 Million USD | 83.376% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 67.752% |
| Quince Therapeutics, Inc. | 34.62 Million USD | 3.726% |
| Rezolute, Inc. | 70.38 Million USD | 52.647% |
| Clene Inc. | 41.07 Million USD | 18.852% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -103.499% |
| BeyondSpring Inc. | 24.86 Million USD | -34.044% |
| Synlogic, Inc. | 58.53 Million USD | 43.057% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -86.285% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -641.987% |
| Peak Bio, Inc. | 1249.13 USD | -2668163.191% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | 44.86% |
| Krystal Biotech, Inc. | 160.42 Million USD | 79.224% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 87.684% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 90.423% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -1445.396% |
| MannKind Corporation | 125.59 Million USD | 73.463% |
| Ikena Oncology, Inc. | 84.57 Million USD | 60.592% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -245.497% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 62.802% |
| Gossamer Bio, Inc. | 183.75 Million USD | 81.862% |
| CohBar, Inc. | 12.38 Million USD | -169.045% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | 34.291% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -20.84% |
| Legend Biotech Corporation | 583.14 Million USD | 94.284% |
| Mural Oncology plc | 192.07 Million USD | 82.647% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 50.363% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -106.439% |
| Disc Medicine, Inc. | 91.12 Million USD | 63.424% |
| Champions Oncology, Inc. | 28.11 Million USD | -18.57% |
| REGENXBIO Inc. | 321.15 Million USD | 89.622% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -521.687% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 40.222% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | 14.452% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 70.854% |
| Vaxart, Inc. | 90.72 Million USD | 63.263% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -291.198% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | 22.115% |
| Cellectis S.A. | 97.32 Million USD | 65.752% |
| Longeveron Inc. | 21.25 Million USD | -56.847% |
| Repare Therapeutics Inc. | 167.35 Million USD | 80.084% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 97.551% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 55.939% |
| Revolution Medicines, Inc. | 498.76 Million USD | 93.317% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -401.053% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | 24.171% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 55.316% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | 52.136% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -201.357% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.302% |
| Denali Therapeutics Inc. | 527.23 Million USD | 93.678% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -285.022% |
| Veru Inc. | 101.34 Million USD | 67.113% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -42.394% |
| Cingulate Inc. | 22.75 Million USD | -46.447% |
| Passage Bio, Inc. | 108.38 Million USD | 69.25% |
| Context Therapeutics Inc. | 25.07 Million USD | -32.934% |
| Exicure, Inc. | 14.07 Million USD | -136.787% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 83.825% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | 23.027% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -263.18% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 86.799% |
| Nuvalent, Inc. | 149.49 Million USD | 77.704% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -313.171% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 67.844% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -55.392% |
| OmniAb, Inc. | 83.89 Million USD | 60.272% |
| Anew Medical, Inc. | 1.3 Million USD | -2462.194% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -1.728% |
| Lipocine Inc. | 15.08 Million USD | -121.02% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | 51.352% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 56.232% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 17.324% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 70.978% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -48.901% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 94.982% |
| Ocugen, Inc. | 71.56 Million USD | 53.428% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 64.492% |
| Q32 Bio Inc. | 92.68 Million USD | 64.037% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -57.41% |
| Alumis Inc. Common Stock | 158.17 Million USD | 78.928% |
| Equillium, Inc. | 50.6 Million USD | 34.138% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | 46.592% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -139.689% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -76.676% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 29.011% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 69.271% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -168.949% |
| Dominari Holdings Inc. | 23.83 Million USD | -39.837% |
| Edesa Biotech, Inc. | 9.22 Million USD | -261.389% |
| vTv Therapeutics Inc. | 11.9 Million USD | -179.92% |
| Bio-Techne Corporation | 563.03 Million USD | 94.08% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 91.847% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 87.598% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 74.803% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -131.282% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 79.639% |
| Nkarta, Inc. | 131.65 Million USD | 74.683% |
| BioCardia, Inc. | 12.12 Million USD | -174.978% |
| Iterum Therapeutics plc | 47.46 Million USD | 29.784% |